Pharma BD Deal Intelligence
BMS to acquire Padlock for up to $600M — the deal complements BMS's existing immunoscience franchise (Orencia at $1.885B annually) with a potentially…
Nature Reviews flags Padlock acquisition as BMS picking up potential keys to treating rheumatoid arthritis through a novel autoantigen-blocking mechanism.
BMS does not appear to be progressing small-molecule PAD4 inhibitors from the Padlock program, instead pursuing PAD4 antibodies in a 2024 patent — implying the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS acquired Cambridge, MA-based Padlock Therapeutics for up to $600M (upfront cash plus development milestones tied to advancement of PAD inhibitor program for rheumatoid arthritis and other autoimmune diseases). Acquisition gave BMS full rights to Padlock's PAD discovery program. Closed Q2 2016.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Padlock Therapeutics, Inc. (this deal) | 2016 | $600M | 27 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2016 deals · Bristol-Myers Squibb Company deals · Immunology deals